glp-1 and nausea Use of agonists prior to THA may increase postoperative nausea, vomiting Is it the meds or

A recent study identified gene variants that appear to affect both weight-loss outcomes and side-effect risk in people taking GLP-1 medications

Gallbladder-related conditions have been observed in clinical trials

To capture population structure specific to the UKBB cohort, we performed principal component analysis of ~150,000 UKBB samples using ~100,000 SNPs

[3] Weight loss typically follows a predictable pattern: Initial phase (0-3 months): Gradual dose escalation with modest weight reduction as appetite suppression begins Active loss phase (3-12 months): Most significant weight reduction occurs during this period Plateau phase (12+ months): Weight stabilises

Nauk et al, 2011